Orsini Partners With Priovant to Support LISRAYA Access
ELK GROVE VILLAGE, Illinois, Aug 28, 2026 Orsini announced that it will serve as a specialty pharmacy partner for...
JAK inhibitor
Advertisement
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
SILVER SPRING, MARYLAND, Aug 27, 2026 Priovant Therapeutics Inc. has received U.S. Food and Drug Administration (FDA) approval for...
Karyopharm Eyes Accelerated FDA Approval for Selinexor
NEWTON, Mass., July 30, 2026 Karyopharm Therapeutics Inc. plans to submit a supplemental New Drug Application (sNDA) to the...
AbbVie Secures EU Approval for RINVOQ in Severe Alopecia Areata
NORTH CHICAGO, Ill., July 29, 2026 AbbVie announced that the European Commission (EC) has approved RINVOQ® (upadacitinib) for the...
Incyte Secures EU Approval for Opzelura Cream in Atopic Dermatitis
WILMINGTON, Del., July 29, 2026 Incyte announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the...
Advertisements
Castle Biosciences Wins NY Approval for AdvanceAD-Tx Test
FRIENDSWOOD, Texas, July 14, 2026 Castle Biosciences, Inc. has announced that its AdvanceAD-Tx™ test has received assay approval from...
Roche Enspryng Gains FDA Priority Review for TED Treatment
BASEL, Switzerland, June 30, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
AbbVie RINVOQ® Moves Closer to EU Approval for Alopecia Areata
NORTH CHICAGO, Ill., June 29, 2026 AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for...
Castle Biosciences Wins 2026 Genomics Innovation Award
FRIENDSWOOD, Texas, May 12, 2026 Castle Biosciences announced that its AdvanceAD-Tx™ gene expression profiling test received the prestigious 2026...
Alkermes Reports Strong Phase 3 LUMRYZ Trial Data
DUBLIN, Ireland, May 12, 2026 Alkermes announced positive topline results from the pivotal REVITALYZ Phase 3 clinical trial evaluating...
Advertisement
